Aim To analyze the expression of HMOX1 and miR-122 in liver biopsy samples obtained from HCV mono-and HIV/HCV co-infected patients in relation to selected clinical parameters, histological examination and IL-28B polymorphism as well as to determine whether HMOX1 expression is dependent on Bach-1. Materials and Methods The study group consisted of 90 patients with CHC: 69 with HCV mono and 21 with HIV/HCV co-infection. RT-PCR was used in the analysis of HMOX1, Bach-1 and miR-122 expression in liver biopsy samples and in the assessment of IL-28B single-nucleotide polymorphism C/T (rs12979860) in the blood. Moreover in liver biopsy samples an analysis of HO-1 and Bach-1 protein level by Western Blot was performed. Results HCV mono-infected patients, with lower grading score (G<2) and higher HCV viral load (>600000 IU/mL) demonstrated higher expression of HMOX1. In patients with HIV/HCV co-infection, the expression of HMOX1 was lower in patients with lower lymphocyte CD4 count and higher HIV viral load. IL28B polymorphism did not affect the expression of either HMOX1 or miR-122. Higher HMOX1 expression correlated with higher expression of Bach-1 (Spearman’s ρ = 0.586, p = 0.000001) and miR-122 (Spearman’s ρ = 0.270, p = 0.014059). Conclusions HMOX1 and miR-122 play an important role in the pathogenesis of CHC in HCV mono-and HIV/HCV co-infected patients. Reduced expression of HMOX1 in patients with HIV/HCV co-infection may indicate a worse prognosis in this group. Our results do not support the importance of Bach-1 in repression of HMOX1 in patients with chronic hepatitis C.
References
[1]
Chen SL, Morgan TR (2006) The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 3: 47–52. doi: 10.7150/ijms.3.47
[2]
Lauer GM, Walker BD (2001) Hepatitis C virus infection. N Engl J Med 345: 41–52. doi: 10.1056/nejm200107053450107
[3]
Koziel MJ, Peters MG (2007) Viral hepatitis in HIV infection. N Engl J Med 356: 1445–1454. doi: 10.1056/nejmra065142
[4]
Caballeria L, Pares A, Castells A, Gines A, Bru C, et al. (2001) Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. Am J Gastroenterol 96: 1160–1163.
[5]
Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, et al. (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364: 2405–2416. doi: 10.1056/nejmoa1012912
[6]
Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, et al. (2011) Boceprevir foruntreated chronic HCV genotype 1 infection. N Engl J Med 364: 1195–1206. doi: 10.1056/nejmoa1010494
[7]
Choi J, Lee KJ, Zheng Y, Yamaga AK, Lai MM, et al. (2004) Reactive oxygen species suppress hepatitis C virus RNA replication in human hepatoma cells. Hepatology 39: 81–89. doi: 10.1002/hep.20001
[8]
Mutlu-Turkoglu U, Ademoglu E, Turkoglu S, Badur S, Uysal M, et al. (1997) The effects of interferonalpha on serum lipid peroxidation and total thiol content in patients with chronic active hepatitis-C. Res Commun Mol Pathol Pharmacol 96: 357–361.
[9]
De Maria N, Colantoni A, Fagiuoli S, Liu GJ, Rogers BK, et al. (1996) Association between reactive oxygen species and disease activity in chronic hepatitis C. Free Radic Biol Med. 21: 291–295. doi: 10.1016/0891-5849(96)00044-5
[10]
Farinati F, Cardin R, De Maria N, Della Libera G, Marafin C, et al. (1995) Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 22: 449–456. doi: 10.1016/0168-8278(95)80108-1
[11]
Shimoda R, Nagashima M, Sakamoto M, Yamaguchi N, Hirohashi S, et al. (1994) Increased formation of oxidative DNA damage, 8-hydroxydeoxyguanosine, in human livers with chronic hepatitis. Cancer Res 54: 3171–3172.
[12]
Wen T, Zhao JY, Mei S, Guan L, Zhang YL (2006) [Protective effect of heme oxygenase-1 and its reaction product, carbon monoxide on acute liver injury induced by carbon tetrachloride in rats]. Beijing Da Xue Xue Bao 38: 618–622.
[13]
Abraham NG, Kappas A (2008) Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 60: 79–127. doi: 10.1124/pr.107.07104
[14]
Zhu Z, Wilson AT, Mathahs MM, Wen F, Brown KE, et al. (2008) Heme oxygenase-1 suppresses hepatitis C virus replication and increases resistance of hepatocytes to oxidant injury. Hepatology 48: 1430–1439. doi: 10.1002/hep.22491
[15]
Shan Y, Zheng J, Lambrecht RW, Bonkovsky HL (2007) Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Gastroenterology 133: 1166–1174. doi: 10.1053/j.gastro.2007.08.002
[16]
Ghaziani T, Shan Y, Lambrecht RW, Donohue SE, Pietschmann T, et al. (2006) HCV proteins increase expression of heme oxygenase-1 (HO-1) and decrease expression of Bach1 in human hepatoma cells. J Hepatol 45: 5–12. doi: 10.1016/j.jhep.2005.12.020
[17]
Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W (2009) Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med 15: 31–33. doi: 10.1038/nm.1902
[18]
Batts KP, Ludwig J (1995) Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 19: 1409–1417. doi: 10.1097/00000478-199512000-00007
[19]
Korenaga M, Wang T, Li Y, Showalter LA, Chan T, et al. (2005) Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem 280: 37481–37488. doi: 10.1074/jbc.m506412200
[20]
Elbirt KK, Bonkovsky HL (1999) Heme oxygenase: recent advances in understanding its regulation and role. Proc Assoc Am Physicians 111: 438–447.
[21]
Takahashi T, Shimizu H, Morimatsu H, Inoue K, Akagi R, et al. (2007) Heme oxygenase-1: a fundamental guardian against oxidative tissue injuries in acute inflammation. Mini Rev Med Chem 7: 745–753. doi: 10.2174/138955707781024517
[22]
Abdalla MY, Ahmad IM, Spitz DR, Schmidt WN, Britigan BE (2005) Hepatitis C virus-core and non structural proteins lead to different effects on cellular antioxidant defenses. J Med Virol 76: 489–497. doi: 10.1002/jmv.20388
[23]
Abdalla MY, Britigan BE, Wen F, Icardi M, McCormick ML, et al. (2004) Down-regulation of heme oxygenase-1 by hepatitis C virus infection in vivo and by the in vitro expression of hepatitis C core protein. J Infect Dis 190: 1109–1118. doi: 10.1086/423488
[24]
Hou WH, Rossi L, Shan Y, Zheng JY, Lambrecht RW, et al. (2009) Iron increases HMOX1 and decreases hepatitis C viral expression in HCV-expressing cells. World J Gastroenterol 15: 4499–4510. doi: 10.3748/wjg.15.4499
[25]
Zhu Z, Wilson AT, Luxon BA, Brown KE, Mathahs MM, et al. (2010) Biliverdin inhibits hepatitis C virus nonstructural 3/4A protease activity: mechanism for the antiviral effects of heme oxygenase? Hepatology 52: 1897–1905. doi: 10.1002/hep.23921
[26]
Fillebeen C, Pantopoulos K (2010) Iron inhibits replication of infectious hepatitis C virus in permissive Huh7.5.1 cells. J Hepatol 53: 995–999. doi: 10.1016/j.jhep.2010.04.044
[27]
Lehmann E, El-Tantawy WH, Ocker M, Bartenschlager R, Lohmann V, et al. (2010) The heme oxygenase 1 product biliverdin interferes with hepatitis C virus replication by increasing antiviral interferon response. Hepatology 51: 398–404. doi: 10.1002/hep.23339
[28]
Kakizaki S, Takagi H, Horiguchi N, Toyoda M, Takayama H, et al. (2000) Iron enhances hepatitis C virus replication in cultured human hepatocytes. Liver 20: 125–128. doi: 10.1034/j.1600-0676.2000.020002125.x
[29]
Jopling CL, Norman KL, Sarnow P (2006) Positive and negative modulation of viral and cellular mRNAs by liver-specific microRNA miR-122. Cold Spring Harb Symp Quant Biol 71: 369–376. doi: 10.1101/sqb.2006.71.022
[30]
Roberts AP, Lewis AP, Jopling CL (2011) miR-122 activates hepatitis C virus translation by a specialized mechanism requiring particular RNA components. Nucleic Acids Res 39: 7716–7729. doi: 10.1093/nar/gkr426
[31]
Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, et al. (2007) Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 449: 919–922. doi: 10.1038/nature06205
[32]
Devadas K, Dhawan S (2006) Hemin activation ameliorates HIV-1 infection via heme oxygenase-1 induction. J Immunol 176: 4252–4257.
